Key Highlights
- The loss was USD 0.23 per share, matching the estimate, against a loss of USD 0.62 a year earlier.
- Net loss was USD 5.36 million against USD 13.88 million; operating expenses were USD 6.20 million against USD 15.15 million.
- The nine month net loss was USD 42.6 million, or USD 1.89 per share, against USD 2.03 a year earlier.
- Cash, cash equivalents and short-term investments were USD 62.9 million, and the accumulated Deficit was USD 302.3 million.
Boundless Bio, Inc. (NASDAQ:BOLD) filed its Quarterly Report for the period ended September 30, 2026, on November 10, 2026. The filing shows a net loss of USD 5,364 thousand, or USD 0.23 per share, against USD 13,879 thousand, or USD 0.62 per share, a year earlier. The source table carried an estimate of negative USD 0.23 per share and no revenue, so the quarter matched the estimate.
Total operating expenses were USD 6,201 thousand against USD 15,148 thousand, and loss from operations was the same amount in each period. General and administrative expenses were USD 4,761 thousand against USD 4,475 thousand. Interest income was USD 572 thousand against USD 1,269 thousand.
Nine Month Results and Merger Costs
For the nine months, net loss was USD 42,612 thousand against USD 45,312 thousand, and the loss per share was USD 1.89 against USD 2.03. Total operating expenses were USD 45,060 thousand against USD 49,550 thousand, with general and administrative expenses of USD 19,913 thousand against USD 14,522 thousand.
The filing states that the company incurred Transaction Costs in connection with its pending merger with another company, Serapha Bio, Inc., of approximately USD 1.3 million for the three months and USD 3.3 million for the nine months. These consist of legal, financial advisory and accounting costs.
The filing also reports charges of approximately USD 0.9 million for the three months and USD 3.6 million for the nine months, of which approximately USD 1.8 million for the nine month period was recorded in Research and Development expense. It states that an amendment accounted for as a modification under accounting standard ASC 718 resulted in USD 2.0 million of stock-based compensation expense in the nine months.
Liquidity and Merger Terms
The filing states that cash, cash equivalents and short-term investments were USD 62.9 million at September 30, 2026. It also states that the accumulated deficit was USD 302.3 million, that net loss for the nine months was USD 42.6 million, and that negative cash flows from operations were USD 46.8 million.
The filing's risk factors state that the merger may not close if its conditions are not satisfied or waived, and that the amount of the anticipated Cash Dividend in connection with the merger may change based on timing, Operating Expense levels and other factors. They also state that the exchange ratio does not change based on the Market Price of the company's common stock.
Items to Follow
The items to follow are the satisfaction of the merger conditions, the size of the anticipated cash dividend, further transaction costs and the cash balance. The company states it is fully remote and maintains no physical offices, and it reported 23,611,406 shares of common stock outstanding on the cover of the filing.
The weighted average share count used in the quarterly per share calculation was 22,865 thousand against 22,386 thousand a year earlier. The filing's legal proceedings and merger related disclosures are reported there and flagged for human legal review.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...